ABSTRACT: Intervertebral disc (IVD) degeneration is the most common cause of low back pain, which affect 80% of the population during their lives, with heavy economic burden. Many factors have been demonstrated to participate in IVD degeneration. In this study, we investigated the role of short stature homeobox 2 (SHOX2) in the development of IVD degeneration. First, we detected the expression of SHOX2 in different stages of human IVD degeneration; then explored the role of SHOX2 on nucleus pulposus (NP) cells proliferation and apoptosis, finally we evaluated the effect of SHOX2 on the production of extracellular matrix in NP cells. Results showed that the expression of SHOX2 is mainly in NP compared with AF tissues, its expression decreased with the severity of human IVD degeneration. TNF-a treatment led to dose-and time-dependent decrease in SHOX2 mRNA, protein expression and promoter activity in NP cells. The silencing of SHOX2 inhibited NP cells proliferation and induced NP cells apoptosis. Finally, SHOX2 silencing led to decreased aggrecan and collagen II expression, along with increased ECM degrading enzymes MMP3 and ADAMTS-5 in NP cells. In summary, our results indicated that SHOX2 plays an important role in the process of IVD degeneration, and might be a protective factor for IVD degeneration. Further studies are required to confirm its exact role, and clarify the mechanism. Keywords: SHOX2 gene; TNF-a; intervertebral disc degeneration Low back pain is a wide spread problem, affecting 80% of the population during their lives, 1 with billions economic costs each year.
Low back pain is a wide spread problem, affecting 80% of the population during their lives, 1 with billions economic costs each year. 2 Recent studies have revealed that intervertebral disc (IVD) degeneration is the most common cause of low back pain, with 40% of the low back pain cases attributed to IVD degeneration. 3 The hallmarks of IVD degeneration are characterized by decreased cell density, 4, 5 decreased extracellular matrix (ECM), 5, 6 and dysregulation of anabolic and catabolic factors. 7, 8 ECM, which mainly consists of collagen type II and aggrecan, 9 plays an important role in the maintenance of the normal function of IVD, but the molecular mechanisms controlling proteoglycan turnover in the degenerated IVD are not well understood. 10 It has been reported that TNF-a can up-regulate the expression of matrix-degrading enzymes, which cleave collagen type II and aggrecan, 11 and play an important role in IVD degeneration. 12, 13 TNF-a was the most selected treatment reagent for IVD degeneration models in vitro.
14 Although many factors participate in IVD degeneration, there is much more to investigate regarding the regulation of IVD cell proliferation and apoptosis, 15, 16 ECM biosynthesis and degradation in normal, and degenerated discs.
Short stature homeobox 2 (SHOX2), a member of the short stature homeobox gene family, is the human paralog of SHOX and is only found in vertebrates. It is essential in the development of the internal skeleton and related structures. 17 Humans have both SHOX and SHOX2. Rodents have only SHOX2, which shares 99% identity at the amino acid level with its human counterpart. 18, 19 Previous studies revealed that inactivation of SHOX2 gene led to severe defects in a number of developing organs, including the heart, palate, temporomandibular joint, and limbs. [20] [21] [22] It has been reported that SHOX2 regulates the process of chondrogenesis at two distinct stages. It prevents the onset of early chondrocyte differentiation and controls the transition of chondrocytes from mature to hypertrophic by regulating the expression of Sox9, Sox6, Acan, Col2a1, Runx2, among others. 23, 24 Nucleus pulposus (NP), which is the main functional unit of IVD and consists of small chondrocyte-like cells with typical morphology, 25 shares a common developmental lineage at the molecular level with cartilage. However, the role of SHOX2 in IVD degeneration has not been reported until now.
In this study, we designed to detect the expression of SHOX2 at different degenerative stages of human IVD, explore the role of SHOX2 on NP cells proliferation and apoptosis, and evaluate the effect of SHOX2 on the production of ECM in NP cells. In this way, we determined the expression pattern of SHOX2, regulation of SHOX2 by TNF-a, and the role of SHOX2 in the regulation of NP cells proliferation and apoptosis and ECM production. Finally, we obtained a preliminary understanding of the role of SHOX2 in the development of IVD degeneration. streptomycin (P/S), trypsin/EDTA, and Ribonucleic acid (RNA) extract reagents were purchased from Invitrogen (Life Technologies, CA). RNeasy Mini columns were purchased from Qiagen. SHOX2, ADAMTS-5, MMP-3, Aggrecan, and Collagen II antibodies were purchased from Cell Signaling or Abcam. b-Tubulin was purchased from Novus Biologicals. TNF-a was purchased from Peprotech, NJ. SHOX2 siRNA was purchased from Santa Cruz Biotech (CA) and Land, Inc. (China), (Table S1 ).
Isolation and Treatment of Rat and Human Nucleus Pulposus Cells
Sprague-Dawley rat NP cells, AF cells, and human NP cells were isolated using a method reported earlier by Risbud et al. 26 The cells were cultured in DMEM and 10% FBS supplemented with antibiotics. To investigate the effect of TNF-a, cells were treated with TNF-a (12.5-100 ng/ml) for 4-24 h. In some experiments, cells were treated with SHOX2 siRNA 24 h before the addition of TNF-a.
Collection and Grading of Human Nucleus Pulposus Tissues
Degenerated human lumbar IVD samples were collected as surgical waste from patients undergoing spinal surgery in our hospital. Control non-degenerated samples were obtained from patients suffering from lumbar fracture or vertebral tumor. Samples were collected according to the approval of the local ethics committee, and informed consent was obtained from every patient or family members before collection. Magnetic resonance imaging (MRI) was performed on patients prior to surgery, assessment of IVD degeneration was performed according to the classification system described by Pfirrmann et al. 27 The samples were divided into four groups: Non-degenerated (grade I/II) with four samples (29.3 AE 5.6 years), mildly degenerated (grade III) with four samples (41.5 AE 5.3 years), moderately degenerated (grade IV) with four samples (51.0 AE 2.2 years), and severely degenerated (grade V) with four samples (60.3 AE 8.5 years). The characteristics of the patients are listed in Table S2 .
IHC Staining for SHOX2
To determine the type and distribution of SHOX2 expression in different stages of degenerated discs, freshly isolated IVDs were immediately fixed in 4% paraformaldehyde and then embedded in paraffin. Similarly, to determine the expression of SHOX2 with aging, rat tail IVDs were obtained from different ages of male Sprague Dawley rats (new born, 1, 2, 4, 8 weeks, and 8 months). The samples were collected according to the approval of the local ethics committee.
After antigen retrieval, quenching of endogenous peroxidase, and blocking of nonspecific binding, the sections were incubated with anti-SHOX2 antibody (ab55740, Abcam; 1:200 dilution), followed by a secondary anti-mouse HRP conjugated DAB detection system and counterstaining with hematoxylin. Sections without the addition of primary antibody were used as negative controls. The specimens were viewed under microscope. The percentage of NP cells with SHOX2 compared with the total number of NP cells was calculated by two independent examiners in a blinded manner.
Real-Time RT-PCR Analysis
The total RNA was extracted from rat AF or NP cells using RNeasy Mini columns (Qiagen) according to the manufacturer's instructions. 26 For human IVD samples, total RNA was isolated from 200-300 mg of IVD tissue. The tissue was homogenized in Trizol (Invitrogen) on ice, using an Omni TH Homogenizer. Then, the RNA was passed through the RNeasy Mini columns. The purified, DNA-free RNA was converted to cDNA using Superscript III Reverse Transcriptase kit (Invitrogen).
Quantitative PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. Reactions were set up in triplicate in 96-well plates. PCR reactions were performed using a StepOnePlus real-time PCR system (Applied Biosystems). The expression values were normalized to those of 18S cDNA and HPRT or b-actin (Table S3) . To verify the amplification specificity, melting curves were analyzed with subsequent gel electrophoresis. The quantification data (DDCT method) represented the mean of duplicate conditions. Protein Extraction and Western Blotting NP or AF cells were placed on ice immediately after treatment, washed with ice-cold PBS, and harvested in mammalian protein extraction reagent buffer (Pierce), reported earlier by Risbud et al. 26 Protein concentrations were measured using a BCA Protein Assay Kit (Pierce).
Total cellular proteins (20 mg per well) were resolved on 8-12% SDS-polyacrylamide gels and transferred using electroblotting to PVDF membranes (Millipore). The membranes were blocked in 5% non-fat dry milk with TBST and incubated overnight at 4˚C with antibodies against SHOX2, aggrecan (sc-25674, Santa Cruz, 1:200), collagen II (ab37712, Abcam, 1:5000), MMP3 (sc-6839, Santa Cruz, 1:200), and Adamts-5 (sc-134952, Santa Cruz, 1:2000). After washing with TBST, the membranes were incubated with anti-rabbit or anti-rat HRP-conjugated secondary antibodies, which were then detected with ECL Plus (Millipore) reagent. The results were then quantified using a multi-gauge densitometry system (Fujifilm, Tokyo, Japan).
SHOX2 Plasmids Construct
To construct the full-length SHOX2 promoter, genomic DNA was isolated from Huh7 cells using a Gentra genomic DNA isolation kit (Qiagen, Valencia, CA). PCR was used to amplify the 1.1 kb SHOX2 promoter [26] (NCBI nucleotide database, 1156) with XhoI-and HindIII-restriction enzyme digestive sites. The fragment was inserted into an XhoI-and HindIII-treated PGL3 luciferase reporter plasmid and was named SHOX2-Luc. R-Shox2-p-F XhoI: cacaactcgagCGGCCGAGGCTATCAGAAAA, R-Shox2-p-R HindIII: tgaaagcttGGCCGTTACCCTCCGTCA (Table S4 ).
Transfections and Dual Luciferase Assay
Transfections and Dual Luciferase assay were used to detect the activity of SHOX2 reporter plasmid. Rat NP cells were transferred to 48-well plates (2 Â 10 4 cells/well) one day before transfection. To measure the effect of TNF-a on SHOX2, cells were transfected with 250 ng of SHOX2 plasmid using 250 ng of pRL-TK plasmid. Lipofectamine 2000 (Invitrogen) was used as a transfection reagent. Twenty-four h after transfection, some cells were treated with TNF-a (50 ng/ml). Forty-eight hours after transfection, the cells were harvested, and a Dual-LuciferaseTM reporter assay system (Promega) was used for sequential measurements of firefly and Renilla luciferase activities. The quantification of luciferase activities and calculation of relative ratios were carried out using TECAN Infinite F500. At least 1048 YE ET AL. three independent transfections were performed, and all analyses were carried out in triplicate.
Cell Counting Kit-8 (CCK-8) Assay
One hundred microliter of NP cell suspensions (5 Â 10 3 cells/ well) in the logarithmic phase were distributed in quadruplicate in 96-well plates. One hundred microliter of culture medium was pipetted into the wells of 96-well plates as a blank control group. The plates were kept in an incubator at 37˚C under 5% CO 2 for 24 h. Briefly, after the treatment, 10 ml of CCK-8 (Kumamoto, Japan) was added to each well, and the plates were incubated for 1 h. The optical density (OD) was measured using a microplate reader (Tecan; Spectra Flour Plus) at 450 nm. The procedure was carried out thrice to obtain the mean values. The percentage of inhibition of proliferation was calculated by (1-mean OD for drug group/mean OD for control group) Â 100%.
Flow Cytometry Analysis for Cell Apoptosis NP cells were trypsinized with 0.25% trypsin-EDTA (Gibco Life Technologies, CA) and collected for the detection of apoptosis using an Annexin V-FITC Apoptosis Detection Kit (BD), according to the manufacturer's instructions. Briefly, NP cells were washed twice with cold PBS and resuspended in 500 ml binding buffer (10 mm HEPESNaOH, pH 7.4, 140 mm NaCl, and 2.5 mm CaCl2) at a concentration of 1 Â 10 6 cells/ml. After the addition of 5 ml Annexin V-FITC solution and propidium solution (PI, 2.5 mg/ml), NP cells were incubated for 15 min at room temperature and then analyzed by flow cytometry (Beckman Coulter, Fullerton, CA). The index for apoptosis was calculated as the number of cells undergoing apoptosis to the total number of cells.
Statistical Analysis
Statistical analyses were performed using SPSS 13. According to the data distribution and the homogeneity of variance, SHOX2 expression distribution among the four degenerative stages was analyzed by one-way ANOVA. The relationship between the grade of IVD and SHOX2 expression were analyzed using a Spearman rank correlation test. All of the cellular measurements were performed in triplicate. Results are presented as the means AE SD. 28 The differences among groups were assessed by analysis of variance. A p < 0.05 was considered statistically significant.
RESULTS
The Expression of SHOX2 Was Prominently in NP Tissue of IVD To determine the expression pattern of SHOX2 in NP and AF tissues, we measured the expression of SHOX2 protein and SHOX2 mRNA levels in mature rat NP and AF tissues. The expression of SHOX2 mRNA is higher in NP than AF tissues (Fig. 1A) . Western blot also showed the expression of SHOX2 protein was more prominent in NP than AF (Fig. 1B/C ).
SHOX2 Expression Decreased With Age
To evaluate the possible link between SHOX2 and age, we measured the expression of SHOX2 at different ages in rats. Sagittal sections of neonatal to skeletally mature rat IVD were stained with anti-SHOX2 antibody. IHC showed that robust immunostaining was detected in NP tissues of neonatal rats, and the expression of SHOX2 decreased with growth and aging, with the lowest level in 8-month-old rat NP tissues (Fig. 1D) Figure 2A . The expression of SHOX2 in different degenerative stages of human IVD was studied using real-time RTPCR and Western blot. Real-time RTPCR analysis indicated that the expression of SHOX2 mRNA was strong in non-degenerated human IVD, which decreased with the severity of IVD degeneration according to the Pfirrmann grade (Fig. 2B) . Western blot analysis also showed similar results ( Fig. 2C/D) .
To further document the involvement of SHOX2 in IVD degeneration, IHC staining was performed using anti-SHOX2. The percentages of SHOX2 positive incidences were: 25.9 AE 4.4% (Pfirrmann grade I/II), 16.2 AE 2.1% (grade III), 7.0 AE 1.8% (grade IV), and 3.0 AE 0.9% (grade V) (Fig. 2E/F) . The Spearman rank correlation test showed significant negative correlation between the severity of human IVD degeneration and SHOX2 positive incidence (r ¼ À0.953, p < 0.001).
The Relationship of SHOX2 and TNF-a in NP Tissue
To evaluate whether there was correlation between TNF-a and SHOX2 expression, we measured the expression of TNF-a in human NP tissues by real-time RTPCR, which showed that the expression of TNF-a mRNA increased with the severity of IVD degeneration (Fig. 3A) . The statistical analysis showed a significant negative correlation between the expression of SHOX2 and TNF-a (r ¼ 0.567, p ¼ 0.022) (Fig. 3B) . This suggested that TNF-a might regulate the expression of SHOX2, so TNF-a was used for further investigation.
Regulation of SHOX2 by TNF-a in NP Cells
TNF-a was used to establish the cellular model of IVD degeneration in vitro.
14 To test the premise that TNF-a regulates the expression of SHOX2, rat NP cells were treated with TNF-a, and the expression of SHOX2 was analyzed. TNF-a treatment resulted in a dose-and time-dependent decrease in the expression of SHOX2 mRNA (Fig. 4A/B) . Western blot and densitometric analyses showed that the expression of SHOX2 protein decreased following TNF-a treatment (Fig. 4E-H) .
To investigate whether the regulation of SHOX2 occurs at the transcriptional level, we measured the activity of a 1.1 kb SHOX2 promoter following TNF-a treatment (Fig. 4C) . TNF-a significantly decreased the activity of the SHOX2 promoter in a dose-dependent manner (Fig. 4D) . The Role of SHOX2 in NP Cell Apoptosis, Proliferation, and ECM Secretion The relationship between SHOX2 and NP cell proliferation was evaluated. CCK8 test showed that treatment with TNF-a led to a slight inhibition of NP cell proliferation, while SHOX2 siRNA significantly suppressed the proliferation of NP cells. Moreover, SHOX2 siRNA can enhance the inhibition of TNF-a in the proliferation of NP cells when treated with TNF-a and SHOX2 siRNA together (Fig. 5A) . Next, NP cell apoptosis was assessed using flow cytometry (Fig. 5B) . Few apoptotic cells were observed in non-treatment group, and the silencing of SHOX2 led to a significant increase in the apoptosis of NP cells.
ROLE OF SHOX2 IN THE DEVELOPMENT OF INTERVERTEBRAL
Finally, we evaluated the role of SHOX2 in the regulation of ECM secretion in NP cells, which were treated with TNF-a either with or without SHOX2 siRNA. First, three SHOX2 siRNA were developed and used to treat NP cells. Immunofluorescence detection of RFP (red fluorescent protein) in the NP cells transduced with siRNA co-expressing RFP showed high transduction efficiency. We used Real-time RT-PCR to analyze the efficiency of the three SHOX2 siRNA, results showed that SHOX2 siRNA1 had the highest transduction efficiency (Fig. 6A/B) . Therefore, SHOX2 siRNA1 was used in the following experiments. Real-time RT-PCR showed that the expression of aggrecan and collagen II decreased after TNF-a treatment or the silencing of SHOX2, and SHOX2 siRNA aggravated the suppression of aggrecan and collagen II mRNA by TNF-a (Fig. 6C-F) . The expression of MMP-3 and ADAMTS-5 increased after TNF-a treatment or the silence of SHOX2, SHOX2 siRNA augmented the induction of MMP-3, and ADAMTS-5 mRNA expression by TNF-a.
Western blot showed similar results, with decreased expression of aggrecan and collagen II cellular protein and increased expression of MMP-3 and ADAMTS-5 protein after SHOX2 siRNA treatment (Fig. 7A-E) .
DISCUSSION
This study demonstrated that SHOX2 decreased with aging and the degenerative process of IVD. Additionally, the expression of SHOX2 was down-regulated by TNF-a treatment of NP cells. Moreover, inhibition of SHOX2 decreased the expression of aggrecan and collagen II in NP cells. These results provide strong support of the hypothesis that SHOX2 plays an important role in the pathogenesis of degenerative disc disease. SHOX2 may be a good option for the biologic treatment of mild and moderate IVD degeneration.
Previous studies have demonstrated that over-expression of SHOX2 in the heart results in abnormal cardiac formation 29 and inactivation of SHOX2 leads to abnormal development of the TMJ. 30 A SHOX2 knock-out resulted in a complete absence of chondrocyte maturation and a marked decrease in chondrocyte proliferation. 22 NP consists of small chondrocyte-like cells with typical morphology 25 that share a common developmental lineage with cartilage at molecular level. We inferred that SHOX2 may also participate in the pathophysiology of IVD. In this study, we found that SHOX2 was expressed both in NP and AF tissues, with higher level in NP tissue. This indicates that SHOX2 has a tissue-specific role, which may possibly be due to the distinct embryological origins of these two tissues.
Next, we evaluated the expression of SHOX2 in different degenerative stages of human IVDs, and 
ROLE OF SHOX2 IN THE DEVELOPMENT OF INTERVERTEBRAL
results showed that the expression of SHOX2 mRNA and protein was high in non-degenerated human IVD, and decreased with the severity of IVD degeneration. To further document the involvement of SHOX2 in IVD degeneration, IHC staining was performed, and results showed a significant negative correlation between the degeneration grade of human IVD and positive incidence of SHOX2. Moreover, we found that SHOX2 expression decreased with aging at different growth stages of rat IVDs. These results suggested that SHOX2 may participate in the progression of IVD degeneration.
Cytokines have been reported to induce IVD degeneration, and TNF-a was used to modulate IVD degeneration at the molecular level.
14 To test the premise that SHOX2 is modulated by inflammation, NP cells were exposed to TNF-a. Results showed a marked decrease in the mRNA and protein levels of SHOX2, indicating that TNF-a can regulate SHOX2. To investigate whether the regulation of SHOX2 by TNF-a occurs at the transcriptional level, we measured the activity of a full length SHOX2 reporter promoter after TNF-a treatment. TNF-a significantly decreased SHOX2 promoter activity in a dose-dependent manner. However, the exact regulation mechanism of SHOX2 by TNF-a requires further investigation.
The pathogenesis of IVD degeneration is thought to be autophagy, senescence or apoptosis of IVD cells, 16, 31 decreased IVD cell proliferation, decreased ECM production, 32 and increased expression of ECM degradative enzymes. 33 Therefore, we evaluated the molecular role of SHOX2 on the pathogenesis of IVD degeneration.
Apoptosis is known to be responsible for IVD degeneration, therefore flow cytometry assay was conducted to determine if there was any alteration in cell apoptosis after treatment with si-SHOX2. Results demonstrated that the number of apoptotic cells increased dramatically in the SHOX2 silencing group compared to control, suggesting that SHOX2 was involved in the regualtion of NP cell apoptosis. This is similar to a previous study, which found that the Relevant to cell proliferation, previous studies have demonstrated that the impact of SHOX2 on proliferation was cell-specific. The regulation of SHOX2 on NP cell proliferation was evaluated, results showed that SHOX2 inhibition by siRNA led to decreased proliferation of NP cells. Further studies are needed to investigate the exact mechanism of SHOX2 on the proliferation of NP cells.
For the regulation of ECM synthesis by SHOX2, we treated NP cells with SHOX2 siRNA and detected the expression of MMP3, ADAMTS-5, aggrecan and collagen II mRNA, and protein. The dysregulation of ECM was associated with the pathology of IVD degeneration, accompanied by an upregulation of MMPs and ADAMTS. 5, 8 It was well-established that elevated MMPs and ADAMTS were responsible for the degradation of ECM during IVD degeneration, which was characterized by the loss of collagen II and aggrecan in ECM.
14 It has been reported that pMes-stop SHOX2 in TMJ resulted in reduction of Col I, Col II, AGG, and Gli2, along with increased cell apoptosis, as well as enhanced MMPs (MMP9 and MMP13) activity in the condyle. 34 Li et al. 30 also reported that the expression of collagen I decreased in the SHOX2 SHOX-KI/KI TMJ disc, aggrecan decreased in the disc and condoyle of SHOX2 SHOX-KI/KI TMJ. Furthermore, they found that MMP9 and MMP13 expression was enhanced in the articular disc of SHOX2 SHOX-KI/KI TMJ. Aza-Carmona et al. 24 found that aggrecan, a major component of the cartilage ECM, was the transcriptional target and cofactor of SHOX2 in limb development. In our study, we found that suppression of SHOX2 by siRNA led to increased MMP3 and Adamts-5 expression, along with decreased aggrecan and collagen II at the mRNA and protein level, suggesting that SHOX2 can modulate ECM synthesis in NP cells.
CONCLUSIONS
In conclusion, we demonstrated for the first time that SHOX2 plays an important role in the process of IVD degeneration. The expression of SHOX2 is more prominent in NP than AF tissue and decreases with aging and the severity of IVD degeneration. TNF-a can suppress the expression of SHOX2. The silencing of SHOX2 can enhance NP cell apoptosis and inhibit NP cell proliferation. Additionally, the silencing of SHOX2 can lead to decreased expression of aggrecan and collagen II, along with increased ECM degrading enzymes MMP3 and Adamts-5, which result in reduced ECM components and IVD degeneration.
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